- Home
- MOLN vs FENC Comparison
MOLN vs FENC Comparison
Compare MOLN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | FENC |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.5M | 372.4M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MOLN | FENC |
|---|---|---|
| Price | $4.30 | $10.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.38 | ★ $14.50 |
| AVG Volume (30 Days) | 1.6K | ★ 217.1K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | $374.07 | $41.08 |
| P/E Ratio | ★ N/A | $177.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.53 | $5.65 |
| 52 Week High | $5.36 | $13.25 |
Technical Indicators
Market Signals| Indicator | MOLN | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 42.37 |
| Support Level | $3.78 | $9.84 |
| Resistance Level | $4.58 | $11.28 |
| Average True Range (ATR) | 0.13 | 0.48 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 52.27 | 20.25 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.